CD39/CD73 Mimics for Hemorrhagic Shock Organ Protection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Hemorrhagic shock results in significant global mortality and morbidity, with survivors facing poor functional outcomes and increased risk of multiple organ failure, acute respiratory distress syndrome, and systemic inflammatory response syndrome, primarily due to systemic ischemia-reperfusion injury.

Innovation Solution

Administration of CD39 and/or CD73 mimics to treat hemorrhagic shock, which mimic the enzymes CD39 and CD73 to enhance extracellular adenosine production, reducing organ damage and inflammation through the A2BR signaling pathway.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional resuscitation therapy is used for hemorrhagic shock, then immediate life support is provided, but multiple organ failure and systemic inflammatory response syndrome develop with poor functional outcomes

Engineering Contradiction:

Improvesurvival rateVSAvoidmultiple organ failure

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces CD39 and CD73 mimics as intermediary substances that mediate between the harmful effects of hemorrhagic shock and the body's natural protective mechanisms. These mimics activate the adenosine signaling pathway, which serves as a protective intermediary response that prevents multiple organ failure and reduces systemic inflammation, thereby improving survival rates without the harmful side effects of conventional resuscitation.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the biochemical parameters of the shock state by introducing exogenous CD39 and CD73 mimics that alter nucleotide metabolism and adenosine signaling. This parameter change shifts the body's response from a harmful pro-inflammatory state to a protective anti-inflammatory state, preventing organ failure while maintaining survival benefits.

Inventive Principle:

Principle #35Parameter changes

2Object-affected harmful factors

If CD39 and CD73 mimics are administered to treat hemorrhagic shock, then multiple organ failure is reduced and survival is improved, but the mechanism involves complex adenosine signaling pathways

Engineering Contradiction:

Improveorgan damageVSAvoidsignaling pathway complexity

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The patent extracts and isolates the critical protective function of CD39 and CD73 enzymes by using mimics that replicate their adenosine-generating activity. This extraction allows the protective mechanism to be applied independently of the complex native enzyme systems, simplifying the therapeutic approach while maintaining the benefits of adenosine signaling without requiring comprehension of the full signaling pathway complexity.

Inventive Principle:

Principle #2Taking out (Extraction)

3Object-affected harmful factors

If CD39 and CD73 mimics are used, then lung permeability and neutrophil infiltration are decreased, but the treatment requires precise dosing and timing

Engineering Contradiction:

Improvelung injuryVSAvoidadministration precision

Core Design Contradiction:

Object-affected harmful factorsVSEase of operation

Solution Approach 1:

The patent applies preliminary action by administering CD39 and CD73 mimics at specific critical time points during hemorrhagic shock treatment. The mimics are given before and during the resuscitation process, preventing lung injury before it fully develops. This timing-based approach simplifies the operational complexity by focusing on key intervention moments rather than requiring continuous precise dosing throughout the entire shock state.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

CD39 and CD73 mimics reduce the risk of multi-organ failure, ameliorate ischemia-reperfusion injury, and decrease lung permeability and neutrophil infiltration, thereby improving survival and functional outcomes in hemorrhagic shock.

Implementation Method 1

CD39 and CD73 mimics enhance extracellular adenosine production

Methodology Applied

Scientific EffectEnzymatic activity: Enzyme

Implementation Method 2

reducing organ damage and inflammation through the A2BR signaling pathway

Methodology Applied

Scientific EffectAdenosine signaling:

Data Source

PatentUS20260041741A1CD39 and CD73 for the therapy of hemorrhagic shock

Publication Date: 2026.02.12 THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

AI summary

Compositions and methods for treating hemorrhagic shock, multiple organ failure resulting from hemorrhagic shock, and organ complications resultant therefrom such as acute respiratory distress syndrome.